PharmaShots’ Post

Aleta Biotherapeutics Doses First Patient with ALETA-001 in P-I/II Trial for the Treatment of R/R B-Cell Malignancies #aletabiotherapeutics #aleta001 #bcellmalignancies #clinicaltrial #monotherapy #safety #efficacy #tolerability #pharmacokinetics #pharmacodynamics #treatment #drugdevelopment #cd19 #tcelltherapy #cd20 #cancercells

More happy news on a Monday...it's our second birthday! 🎂 Ashfield, part of UDG Healthcare (now Inizio) and Huntsworth Health (now Inizio) came together two years ago, on 30th June, to become #inizio. A global pharmaceutical commercialisation partner, made up of four distinct divisions of Inizio Advisory, Inizio Medical, Inizio Engage (that's me 🙋♀️ ) and Inizio Evoke. We have achieved so much in two years - check it out below ⬇ We have such a rich and diverse set of capabilities across the 12,000 of us spread over 50 markets globally 🌎 From the deeply scientific and evidence-driven, to the ingeniously creative and experiential; from the external customer and stakeholder landscape, to the internal employee and shareholder landscape. If you're curious and wondering who we are, and what we do - get in touch, happy to have a virtual coffee to explain more ☕ #ReimagineHealth #ConnectedCapabilities #Commercialization #ProductLaunch #CustomerEngagement #EmployeeEngagement #Experience #Design #HappyBirthday #Anniversary #Pharma #Pharmaceuticals #BioPharma #LifeSciences

🎉 Happy birthday Inizio 🎂 We know, you know, most of our agencies are over 30 years old!... 😉 Yet the Inizio brand, the fact that we have consolidated under ONE the constellations of our agencies, is 2 years old 💥 And we are a launch powerhouse!!!! ✅ 50% of all product launches in the last 2 years have been supported by Inizio ✅ 95% of the top performing products were launched in [partnership with Inizio ✅ >40% of Inizio-supported assets are projected to be blockbuster products Read move about our latest capabilities below 👇 🥂 Proud to celebrate this incredible milestone with all of you. #ReimagineHealth #Healthcare #Pharma #Commercialization

We optimize antibodies for affinity, developability, and minimal off-target effects. Our AI-driven methods ensure that final candidates are ready for functional validations and pre-clinical studies. 📊 Find Out More: The key to developing high-quality therapeutic leads. 🌐 mabsilico.com #DrugDiscovery #Innovation #Therapeutics

The landscape of clinical trials for digital therapeutics is evolving, and it’s becoming more rigorous than ever. Faced with skepticism, companies like Swing Therapeutics, Inc. are leading the way by conducting sophisticated studies to validate their digital health solutions. 🔬 Swing Therapeutics’ pivotal trial for its fibromyalgia treatment, Stanza, used a “sham application” to ensure rigorous control. This trial design helps prove the app’s effectiveness beyond a placebo effect. 📊 The study, published in The Lancet, showed significant improvements in participants using Stanza compared to the control group. This rigor in trial design is now becoming a standard practice, influenced by the FDA’s evolving guidelines. 🌍 The shift towards more stringent clinical trials is a crucial step in gaining broader acceptance and potential reimbursement from insurers. 🤷🏽♂️ Diversity of participants is still an issue in digital theraputics trials which tend to skew white and female. As the industry matures, it’s encouraging to see digital therapeutics developers heeding the call for higher standards. This not only enhances credibility but also paves the way for more robust real-world applications. #DigitalTherapeutics #ClinicalTrials #HealthcareInnovation #HealthTech #EvidenceBasedMedicine

Bristol Myers Squibb Presents Results from three P-III Studies of Breyanzi for Treating Various B-Cell Malignancies at ASCO 2024  #bms #breyanzi #largebcelllymphoma #mantlecelllymphoma #follicularlymphoma #clinicaltrial #phase3 #transform #transcendnhl001 #transcendfl

EY-Parthenon & Innoplexus - a Partex Company's Second Edition of the Autoimmune Innovation Index is Out Now! The report captures the evolving clinical landscape across autoimmune diseases, featuring key global pharma and biotech players working on novel therapeutic modalities to advance these diseases. "In this second edition of the Innovation Index, we, along with experts from EY, have evaluated the changing therapeutic landscape for 18 key autoimmune indications. The focus is on new disease-modifying treatments, novel mechanisms of action, innovative combinatorial or targeted approaches, and recent special approvals by the FDA. We predict the clinical success of late-stage trials launched between April 2022 and June 2023 to identify promising companies, assets, and interventions that will lead the way for better patient care in the future." Dr. Gunjan Bhardwaj, Founder & CEO, Partex NV Check out our second edition published: https://lnkd.in/dwMgmf_w Authors: Dr. Gunjan Bhardwaj Dr. Ying Strebe Klaus Ort Dr. Sanika Bhide Ph.D #innovation #biopharma #pharmanews #healthcare #EY #research #autoimmunedisease #partex Nitish Jain, CFA, Dr. Tapashi Mandal, Ph.D. Aastha Ahuja

Roche to Present Data from the P-III (OCARINA II) Clinical Evaluation of Ocrevus to Treat Progressive and Relapsing Multiple Sclerosis #roche #ocrevus #multiplesclerosis #clinicaltrial #phase3 #treatment #safety #efficacy #progressive #relapse #pharmacokinetics #usfda #ema #ocarina2

In a new study, Novo Nordisk's liraglutide daily injections, currently used to treat diabetes and obesity, have shown promise in slowing Alzheimer's progression. The mid-stage clinical trial indicates that liraglutide may protect brain function, with patients experiencing an 18% slower cognitive decline and significantly less brain shrinkage. Other drugs that have been widely known for secondary uses include minoxidil, originally approved for treating high blood pressure, and now recognized as one of the most successful hair regrowth treatments on the market, and aspirin, developed as a pain reliever, which is now widely used to prevent blood clots and to reduce the risk of heart attack and stroke. These findings underscore the benefits of using clinical trials to discover additional uses for approved drugs, a method that could speed up drug delivery and offer new hope to those suffering with a range of illnesses. Learn about how you can speed up your upcoming clinical trials with automated data streaming. https://buff.ly/46vyz85 #ClinicalTrials #PharmaceuticalResearch #HealthcareInnovation

Come meet me at the upcoming GLP-1-Based Therapeutics Summit, where I'll be sharing insights on real-world GLP-1 prescribing trends gleaned from Truveta Data.  #GLP1Summit #GLP1 #PrescriptionTrends #PrescribingTrends